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Prevention of postpartum haemorrhage at community level: 
which uterotonic?
Despite a substantial reduction in global maternal 
deaths due to postpartum haemorrhage between 
1990 and 2013 (from 71 295 to 44 190), this condition 
continues to be the main cause of maternal mortality 
worldwide.1 In sub-Saharan Africa and south Asia, 
many women still deliver at home without a skilled 
attendant, or attended by low-level providers in 
facilities with limited resources.2 In these contexts, 
availability of uterotonics that are easy to administer 
and are stable in ﬁ eld conditions are fundamental to 
decrease the morbidity and mortality of postpartum 
haemorrhage. 
Oxytocin is recommended by WHO, whereas 
misoprostol is recommended only when oxytocin 
is not available or cannot be given.3 Although the 
results one of the largest facility-based randomised 
controlled trials,4 in which misoprostol was compared 
with oxytocin in its original vial formulation, showed 
oxytocin to be signiﬁ cantly more eﬃ  cacious than 
misoprostol in settings with well equipped facilities, 
several questions remained unanswered. For example, 
the clinical signiﬁ cance of the results was small, 
study sites diﬀ ered substantially, and oxytocin was 
not always given intramuscularly (sometimes it was 
given intravenously). Furthermore, because of its 
route of delivery, oxytocin has limited applicability 
in resource-poor settings, especially when women 
deliver without a skilled provider. Thus, the debate 
about misoprostol versus oxytocin during the third 
stage of labour continued. The Uniject formulation 
(ie, via a preﬁ lled single-use intramuscular injection) 
oﬀ ered hope because it could surmount some of the 
community-based limitations that vial formulations of 
oxytocin present.
In an Article in The Lancet Global Health,5 
Ayisha Diop and colleagues answer some of these 
questions. They did a cluster-randomised controlled 
trial in Senegal to investigate the eﬃ  cacy of oxytocin 
in Uniject (10 IU intramuscularly) versus misoprostol 
(600 μg orally) for the prevention of postpartum 
haemorrhage.5 Haemoglobin measurements for 
1049 women delivering in maternity huts were 
See Articles page e37gathered for the primary outcome—mean change in 
haemoglobin concentrations. Results suggested that 
oxytocin in Uniject was not superior to misoprostol. 
Furthermore, oxytocin in Uniject was associated 
with additional programmatic limitations such as its 
limited shelf life when not refrigerated, making the 
choice between the two uterotonics clearer in low-
resource settings. 
The results of this trial are timely and extremely 
important. They contribute to the body of evidence 
on uterotonic choice for ﬁ rst-line prophylaxis in 
addition to shedding light on which uterotonic to 
use in limited-resource settings, taking into account 
formulation and programmatic feasibility. The Article 
ﬁ ts well within health-systems research and action. 
Many countries are trying to optimise the health-
care workforce, and, in the context of maternal 
mortality, postpartum haemorrhage and uterotonic 
use are at the forefront of these discussions. Although 
updates to the WHO recommendations about the 
use of uterotonics for the prevention of postpartum 
haemorrhage might take some years, eﬀ orts to 
disseminate these results widely are important. The 
key messages include that countries already using 
misoprostol at community level should continue to 
do so, and countries that have not yet started should 
accelerate implementation. Available evidence shows 
that misoprostol is a viable option at community level 
to prevent postpartum haemorrhage. 
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